BioVie Inc.

Healthcare · Biotechnology · United States

Last price 1.43 USD (Oct 30, 2026, 3:25 PM EDT) · Market cap 10.79M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to mo...